Jaypirca® (pirtobrutinib)
for Leukemia

Jaypirca (pirtobrutinib) is an oral, non-covalent BTK inhibitor used for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). It targets BTK, an enzyme involved in cancerous B-cell growth, slowing or stopping disease progression. Jaypirca helps patients previously treated with covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib).

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia